Chronic pruritus is defined as itching lasting more than six weeks and affects as many as 22% of individuals during their lifetime, accounting for 1% of annual hospital visits in the United States.^1,2 It is experienced across all demographics, regardless of age, gender, or socioeconomic background.³ Beyond the physical effects, chronic pruritus is linked to sleep disturbances, anxiety, depression, and even suicidal ideation, highlighting its profound impact on mental health.⁴

Recent research has shown that individuals with chronic pruritus experience significant impairments in daily functioning, including challenges at work, disrupted social interactions, and feelings of frustration and emotional distress.⁵ However, despite its impact, chronic pruritus is frequently underrecognized and inadequately treated in clinical settings.¹

The underlying mechanisms of chronic pruritus remain incompletely understood but involve complex interactions between cytokines, sensory neurons, and cutaneous and central nervous system receptors.⁶ It is suggested that chronic itch is driven by peripheral and central sensitization, dysregulated neuroimmune signaling, and psychological factors.^7,8 This evolving view has shifted the focus from purely symptomatic relief to targeting underlying mechanisms, including neural circuits, inflammatory mediators, and cognitive-emotional pathways.

Nonpharmacologic treatments for chronic pruritus include diverse approaches aimed at modifying itch pathways or altering the perception of itch.⁶ Some methods can be effective independently, but are typically most beneficial when used alongside traditional pharmacologic therapies.⁶ These interventions may help reduce medication reliance, minimize side effects, and improve patient adherence, making them valuable additions to conventional treatment strategies. This is especially important because many commonly used treatments, such as antihistamines and corticosteroids, provide only limited or temporary benefit, particularly in cases where the itch arises from neuropathic or psychogenic causes.⁸

Given the multifactorial pathophysiology of pruritus, nonpharmacological interventions can be thought about in three main domains: 1) neural modulation interventions that act on peripheral or central nerve pathways; 2) mind-body interventions that can change the brain’s perception of itch and modify scratching behavior; 3) barrier and environmental approaches that alter the immediate external environment around the skin (see Table). This review explores their mechanisms, clinical applications, and potential role in managing chronic pruritus.

335352

Neuromodulatory interventions disrupt itch signaling by targeting the peripheral or central nervous system.⁹ By altering how signals are transmitted and perceived, relief can be provided from the feeling of itch as an adjunctive, or when traditional pharmacologic therapies are limited. Some of the most common nonpharmacological neuromodulation approaches include phototherapy, transcutaneous electrical nerve stimulation (TENS), cryotherapy, heat therapy, and acupuncture.

Light has been used for centuries to treat skin conditions, with ultraviolet (UV) light serving as a cornerstone therapy due to its ability to reduce cutaneous inflammation.^6,10 UV light can further be broken down into UVA and UVB. UVA light targets a broader range of inflammatory cells, including T lymphocytes, mast cells, and dermal dendritic cells.¹¹ Still, when combined with the photosensitizing agent psoralen, it carries a higher risk of carcinogenesis compared to narrowband UVB therapy.¹² In contrast, UVB radiation reduces inflammation by targeting epidermal keratinocytes and Langerhans cells and decreases histamine release through changes in mast cell membrane phospholipid metabolism.¹³ Though UVB radiation is associated with carcinogenic effects, even extended use of narrowband UVB therapy is considered to have a very low likelihood of causing skin cancer.¹⁴

Phototherapy has proven effective for the relief of pruritus for a range of conditions, including psoriasis, atopic dermatitis (AD), prurigo nodularis (PN), uremic pruritus, unspecified pruritus, and pruritus associated with conditions like lichen planus and cutaneous mastocytosis, among others.¹⁵ Three times weekly narrowband (NB)-UVB therapy achieved Psoriasis Area and Severity Index (PASI) 75, at least a 75% improvement in psoriasis severity and skin clearance, in 70 to 80% of patients after 6 to 12 weeks.¹⁵ Although PASI doesn’t directly measure itch, it can serve as an estimate of itch severity. Phototherapy is considered safe and effective, with most side effects stemming from the varying skin penetration of UV radiation.¹⁶ UVB primarily causes more superficial epidermal reactions like erythema, and UVA can lead to photodamage due to deeper dermis penetration.¹⁷

In AD patients, there have been several randomized controlled trials (RCTs) that support NB-UVB for the treatment of itch. One study found that visual analogue scale (VAS) scores, a measure of itch intensity, significantly decreased from 9.4 to 4.0 following consistent treatment with NB-UVB, with improvements being experienced by patients around 8 weeks.¹⁸ A systematic review reported that NB-UVB increased the likelihood of clinically meaningful itch reduction at approximately 12 weeks compared with placebo.¹⁹

Phototherapy is one of the few nonpharmacologic treatments with substantial clinical evidence supporting its efficacy for pruritus. In particular, NB-UVB has demonstrated broad applicability across inflammatory and noninflammatory pruritic conditions.²⁰ Despite its effectiveness, phototherapy has limitations, including limited access in community settings, the need for frequent clinic visits, and variability in insurance coverage.²¹ However, NB-UVB can serve as an excellent primary or adjunctive treatment, as demonstrated by a study showing that it dropped the median amount of topical corticosteroids from 37.5 g/month to 19.7 g/month used by AD patients.²²

Transcutaneous electrical nerve stimulation (TENS) uses electric currents through cutaneous patches to treat various disorders.²³ It has recently gained attention as an antipruritic therapy after decades of use for pain management.⁶ TENS works by inhibiting C fiber-mediated neurotransmission through a process known as “gating,” effectively reducing itch and pain signals.²⁴

In practice, electrodes are typically placed directly over pruritic areas or along adjacent dermatomes thought to correspond to the involved nerve pathways. Commercially available TENS units vary in size and configuration, with differing electrode sizes and programmable settings, allowing for individualized use in home settings.

A recent study demonstrated that applying TENS three times weekly for up to 12 sessions significantly improved pruritus in patients with AD and lichen simplex chronicus, with itch intensity measured by the VAS, declining by approximately 5 points and remaining significantly lower one month post-treatment (p < 0.001).²⁵ In other cases, TENS has shown effectiveness for itch related to mixed-thickness burns and scrotal neuropathic pruritus.^26,27 TENS is generally safe, but it should be avoided by patients who are pregnant, have seizure disorders, or use pacemakers.⁶ These safety considerations should be reviewed with patients prior to home use.

TENS is a practical modality that has demonstrated antipruritic effects in several small studies. Its ease of use, favorable safety profile, and potential for home application make it an attractive adjunctive option for chronic pruritus.²⁵ Although current evidence is limited by study heterogeneity and small sample sizes, its accessibility and noninvasive nature make it a promising candidate for broader integration into clinical care.²⁸ However, these studies demonstrate the potential of patient-administered therapies like TENS and how they may become increasingly valuable in personalizing long-term itch management.

Whole-body cryotherapy involves brief exposure to cold air in a specially designed chamber, often reaching temperatures as low as −110°C.²⁹ Patients are typically exposed for a few minutes while wearing protective garments to minimize the risk of cold-related injury.²⁹ Cryotherapy reduces itch by altering nerve signal transmission at low temperatures, likely by slowing conduction along cutaneous C fibers and Aδ nerves responsible for transmitting itch and pain signals to the brain.³⁰ While not widely studied for pruritic skin disorders, one study found that whole-body cryotherapy led to a modest decrease in pruritus severity for patients with AD after a month of three weekly sessions in progressively colder chambers.³⁰ However, the results should be interpreted cautiously, as there was no placebo comparison, and some participants experienced mild frostbite. Liquid nitrogen cryotherapy has shown temporary benefits for pruritic conditions such as psoriasis, PN, and chronic pruritus ani, with reports of itch relief and lesion improvement lasting several months.^31–33 However, its use is limited by potential side effects, including skin atrophy, hypopigmentation, procedural pain, and post-treatment drainage.^31,33

Brief application of heat to localized areas has been shown in recent clinical trials to reduce itch intensity in AD. A randomized real-life and experimental study using a 5-second application of noxious heat at 49 °C found an immediate and significant reduction in itch, both for mechanically induced itch and during daily itch episodes, with no loss of effectiveness over repeated applications.³⁴ It has been suggested that activation and desensitization of heat-sensitive ion channels, particularly TRPV1, in nerve endings in the epidermis, control this antipruritic effect.³⁵ In contrast, studies involving healthy volunteers with experimentally induced itch found that short-term warming at lower levels of heat, ranging from 38-41 °C, demonstrated no significant effects on histamine or serotonin-induced itch, highlighting that higher temperatures may be required for relief.^36,37 Because 49 °C is in the noxious range, careful application and avoidance of prolonged contact are necessary to prevent burns.

Acupuncture, a key component of traditional Chinese medicine, has been explored as a potential therapy for pruritus. While clinical trials on acupuncture are challenging to design due to difficulties in blinding and controlling for placebo effects, some evidence suggests it may help reduce itch. It is hypothesized that acupuncture may help reduce itch by lowering immune cell activity, affecting nerve fibers that transmit itch signals, and influencing sensory pathways involved in skin irritation.^38–40 A study on uremic pruritus found that patients who received acupuncture three times per week for a month experienced an approximately 45% reduction in itch, with improvements persisting for up to three months.⁴¹ Another small study found that acupressure helped relieve itching associated with AD.⁴² However, due to the lack of rigorous controls in many studies, it remains challenging to determine whether acupuncture’s benefits are genuinely therapeutic or primarily driven by placebo effects.⁴³

Mind-body interventions aim to reduce feelings of itch by modifying how they are perceived or changing the way people act when they experience the urge to scratch.⁹ These nonpharmacological methods target chronic pruritus’ cognitive, emotional, and behavioral dimensions to improve symptoms.⁹ Approaches in this category include cognitive behavioral therapy (CBT), meditation and mindfulness, psychotherapy, biofeedback, relaxation therapy, music therapy, and massage therapy.

Psychotherapy offers a range of approaches that can help modify the perception of itch and associated behaviors while also addressing anxiety, stress, and sleep disturbances linked to chronic pruritus.⁶ Cognitive behavioral therapy is a structured, evidence-based form of psychotherapy and represents the most extensively studied psychotherapeutic intervention for itch.⁴⁴

An RCT found that patients with AD who completed a 12-week CBT program alongside dermatologic education experienced a reduction in itch severity and scratching frequency, with some also requiring less topical steroid use compared to those who received education alone.⁴⁵

Beyond CBT, other psychotherapeutic approaches have demonstrated potential benefits in managing itch-related distress and behaviors. Habit reversal training, a behavioral psychotherapy developed initially for tic disorders, has been studied in AD and prurigo nodularis, though evidence remains limited.⁴⁶ Support groups for children with AD have been shown to improve quality of life and reduce itch severity, with one study reporting that children who participated, along with their parents, experienced less frequent pruritus compared to those in a control group after six months of biweekly sessions.⁴⁷ Hypnosis, which induces a focused trance-like state through guided imagery or relaxation, has shown benefit in small studies when combined with stress management or biofeedback for conditions such as AD and chronic urticaria.^48–51

CBT targets the psychological and behavioral drivers of the itch-scratch cycle.⁵² A randomized controlled trial of internet-delivered, exposure-based CBT over 12 weeks in adults with moderate-to-severe AD demonstrated significant reductions in itch intensity, perceived stress, sleep disturbance, and depression, with effects maintained at 12-month follow-up.⁵³ Another RCT of a CBT-based itch-coping group program in adults with AD similarly reported reduced itch and scratching, along with decreased corticosteroid and antihistamine use, with benefits sustained at three- and 12-month follow-up.⁵⁴

For other chronic pruritic conditions, evidence for CBT remains limited. In psoriasis, therapist-guided internet-based CBT improved functioning and disease impact, though pruritus was not a primary outcome.⁵⁵ In chronic urticaria and chronic pruritus of unknown origin, RCTs demonstrating antipruritic effects of CBT are lacking.⁵⁶ These findings indicate that while CBT is effective for AD, its role in other pruritic conditions remains uncertain and warrants further investigation.

Meditation has been shown to reduce the brain’s response to pain and itch by decreasing activity in the primary somatosensory cortex, a region responsible for processing these sensations.⁵⁷ Although research is limited, early findings suggest that mindfulness-based meditation may offer symptom relief for patients with chronic pruritus. In a small study of 10 adults with chronic pruritus, an eight-week meditation course improved itch severity, sleep quality, and overall well-being.⁵⁸ The study revealed a significant correlation between meditation session attendance and improvement in itch-specific quality of life measured by the ItchyQoL instrument (r = 0.87, p = 0.02) for all those who attended at least 75% of the classes.⁵⁸ While promising, these findings are limited by the small sample size.

Relaxation techniques are often used in dermatology as supportive interventions to reduce sympathetic arousal that can intensify the itch-scratch cycle. Progressive muscle relaxation (PMR) is a structured relaxation method. In an RCT of 25 adults with AD, those assigned to PMR for one month experienced significant reductions in pruritus, sleep loss, and state anxiety compared with controls, although eczema severity scores did not differ significantly between groups.⁵⁹ In psoriasis, a controlled trial of mindfulness-based stress reduction delivered alongside phototherapy or photochemotherapy found that participants achieved faster skin clearing and reported reductions in symptom-related distress, including itch discomfort, and improved quality of life.⁶⁰ Taken together, these findings suggest that while relaxation therapy is not standalone, it may enhance coping and provide symptom relief in patients with chronic pruritus, particularly when integrated into multidisciplinary care.

Music therapy has been explored as a supportive approach to itch control. In a randomized inpatient study of 50 patients with psoriasis, AD, and other dermatoses, those randomized to a single music intervention session experienced a significantly greater reduction in pruritus intensity one hour after the intervention compared with an emollient cream control (mean numerical rating scale decrease 2.3 vs 1.2 points).⁶¹ Evidence beyond this trial remains limited, but these findings suggest music may offer short-term symptomatic relief as a low-risk adjunctive treatment in those with varying dermatological conditions.

Massage therapy has been considered as a supportive approach for patients with chronic pruritic skin disease. In an RCT of 20 children with moderate AD, daily 20-minute parent-administered massage for one month, in addition to standard topical therapy, led to significantly greater reductions in pruritus severity, sleep disturbance, and overall disease activity as measured by SCORing AD (SCORAD) compared with topical therapy alone.⁶² A more recent RCT in 66 infants with eczema found that mother-performed massage combined with routine care significantly reduced eczema severity (EASI), improved dermatology-related quality of life (IDQOL) score, and lowered relapse rates compared to routine care alone, although pruritus was not directly measured.⁶³ These findings suggest that massage may offer adjunctive benefit, specifically in pediatric AD. Still, the evidence base is limited as pruritus outcomes are underexplored, and no trials have evaluated adult populations.

Barrier-focused interventions aim to restore stratum corneum integrity, reduce transepidermal water loss, and minimize exposure to irritants, thereby decreasing itch triggers and supporting treatment adherence.

Clothing is an often-overlooked factor that can impact chronic pruritic skin disease, either relieving or aggravating symptoms.⁶⁴ A randomized trial in pediatric patients found that untreated silk garments did not significantly relieve pruritus.⁶⁴ However, in multiple studies, silk textiles infused with antimicrobial agents have reduced pruritus and the volume of topical corticosteroid use.⁶⁵ Other innovative textiles, including seaweed-silver fabrics, have antimicrobial and barrier-restorative properties, but studies on their effectiveness for pruritus have shown mixed and inconclusive results.^66,67 Other therapeutic textiles, such as zinc-oxide-treated clothing, support barrier benefits; however, evidence for direct itch reduction is limited, while tourmaline-infused fabrics, which emit infrared radiation, have demonstrated statistically significant itch reduction.^68,69

Wet-wrap therapy involves applying a damp layer of bandages or garments over topical corticosteroids or emollients, usually for several hours or overnight. The occlusion enhances skin hydration, reduces barrier disruption, and increases penetration of the applied agent.⁷⁰ In a prospective RCT of children with severe AD, wet-wraps with diluted topical corticosteroids produced faster and greater short-term improvements in objective SCORAD over 4 weeks compared with emollient-only wraps.⁷¹ As prolonged use of wet-wraps can increase the risk of systemic corticosteroid absorption, secondary infection, and skin maceration, it is generally recommended only for limited durations under clinical supervision.^70,72

Nonpharmacologic therapies for chronic pruritus offer a range of promising interventions. However, many of these approaches remain supported by limited evidence, often derived from smaller sample sizes or studies with methodological challenges. While these therapies may relieve itch in some instances, their true efficacy is unknown in many cases. This underscores the need for more extensive, controlled trials. Specific approaches, particularly narrowband UVB phototherapy, are supported by more substantial evidence; however, even this is best utilized as an adjunctive treatment rather than a standalone therapy. It is apparent that these treatments will be most effective across all modalities when integrated into a comprehensive management plan alongside conventional pharmacologic options. Dermatologists and other healthcare providers should continue exploring these therapies in tandem with traditional treatments to address the multifaceted nature of chronic pruritus.

Future research should prioritize larger, well-designed trials with standardized itch outcome measures to clarify the true efficacy of these interventions. Until such evidence is available, clinicians should view nonpharmacologic therapies as complementary strategies that may reduce symptom burden, improve quality of life, and minimize reliance on medications, while recognizing that their role is supportive rather than curative.